引用本文:[点击复制]
[点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 30次   下载 33  
首发抑郁症患者血浆单核细胞趋化蛋白1水平变化与性别 及体质量指数的关系
孙作厘周佳周晶晶贺毅杨健
0
()
摘要:
目的 探讨首发抑郁症患者血浆单核细胞趋化蛋白1(MCP-1)水平的变化及其与体质量指 数(BMI)及性别的关系。方法 采用前瞻性病例对照研究方法,连续纳入首发抑郁症患者(符合美国精 神疾病诊断和统计手册第IV 版重性抑郁障碍诊断标准)47 例作为研究对象,选取年龄、性别匹配的健康 人群91 名作为对照组。采用MILLIPLEX MAP液相芯片分析系统检测受试者血浆中MCP-1 的水平,分 析首发抑郁症组与对照组之间的差异,并将受试者根据BMI 的不同分为体质量过低、正常、超重及肥胖 人群,分析抑郁症患者不同BMI 分级人群中MCP-1 水平的变化及与性别的关系。结果 首发抑郁症患 者血浆MCP-1 水平为(197.61±60.73)ng/L,明显低于对照组[(222.29±65.49)ng/L],差异有统计学意义 (P=0.035);在对照组和抑郁症组中,血浆MCP-1 水平与BMI 均呈正相关(对照组:r=0.360,P< 0.01;抑郁 症组:r=0.435,P=0.003);抑郁症组中体质量过低+体质量正常患者MCP-1 水平[(181.21±47.12)ng/L]明 显低于对照组体质量过低+体质量正常者[(212.54±64.35)ng/L;t=2.481,P=0.015],在超重及肥胖人群, 两组MCP-1水平差异均无统计学意义(均P>0.05);抑郁症组男性血浆MCP-1水平[(207.86±59.54)ng/L] 较对照组男性[(262.95±66.24)ng/L]降低,差异有统计学意义(t=2.829,P=0.007);在女性中,两组 MCP-1 水平差异无统计学意义(P=0.639)。结论 首发抑郁症患者,尤其是男性患者血浆MCP-1 水平显 著降低,且MCP-1 水平的降低与抑郁症患者的肥胖程度有关,提示MCP-1 与肥胖的相互作用与抑郁的 发生、发展密切相关。
关键词:  首发抑郁症  单核细胞趋化蛋白  体质量指数  性别
DOI:10.3969/j.issn.1009-6574.2020.05.004
基金项目:国家重点研发计划(2016YFC1307200);北京市优秀人才培养资助青年拔尖个人(2018000021223ZK36); 北京市医院管理中心“青苗”计划(QML20181901);北京市属医院科研培育计划(PX2018064 & PX2018065)
Changes of plasma monocyte chemoattractant protein-1 level and its relationship with body mass indexand gender in patients with first-episode major depressive disorder
Sun Zuoli, Zhou Jia, Zhou Jingjing, He Yi, Yang Jian
()
Abstract:
Objective To investigate the changes of plasma monocyte chemoattractant protein-1 (MCP-1) and its relationship with body mass index( BMI) and gender in patients with first-episode major depressive disorder( fMDD). Methods In this prospective case-control study, 47 first-episode depressive patients( meeting the diagnostic criteria for major depressive disorder, fourth edition of the diagnostic and Statistical Manual of mental illness) were enrolled as the research subjects. 91 health individuals matched in age and sex were enrolled as the control group. The plasma level of MCP-1 was measured by MILLIPLEX MAP liquid chip system. The difference of MCP-1 levels was analyzed between fMDD patients and controls. In order to analyze the relationship between MCP-1 and BMI, gender, the participants were divided into underweight, normal, overweight and obese groups according to BMI. Results The plasma MCP-1 levels in fMDD patients were( 197.61±60.73)ng/L, which was lower than that in the control group( 222.29±65.49) ng/L P=0.035). The level of plasma MCP-1 was positively correlated with BMI in both healthy controls( r=0.360, P<0.001) and fMDD patients( r=0.435,P=0.003). The MCP-1 level of fMDD patients with low and normal BMI [(181.21±47.12)ng/L] was significantly lower than that of controls with low and normal BMI[ (212.54±64.35)ng/L; t=2.481,P=0.015]. There was no statistical significance in the MCP-1 level difference between the two groups in overweight and obese participants( P> 0.05). The MCP-1 level of male participants in fMDD group [(207.86±59.54)ng/L] was lower than that in the control group[ (262.95±66.24)ng/L], with statistical significance( t=2.829,P=0.007). There was no significant change in MCP-1 levels in female patients compared with the controls( P=0.639). Conclusions The results indicated the plasma MCP-1 levels were significantly reduced in the fMDD patients compared to controls, especially in male patients, and the decrease of MCP-1 level was related to the degree of obesity in fMDD patients, suggesting that the interaction between MCP-1 and obesity was closely related to depression.
Key words:  First-episode major depressive disorder  Monocyte chemoattractant protein-1  Body mass index  Gender

用微信扫一扫

用微信扫一扫